Table 7.
Treatment Outcomes (Cure/Complete Versus Failure/Relapse) According to Drug Susceptibility Testing Using Recommended or Higher Than Recommended Critical Concentrations Among Patients Who Took That Druga
| Recommended Critical Concentration |
Higher Critical Concentration |
|||
|---|---|---|---|---|
| DST for Drug | OR of Treatment Success if Susceptible to the Drug Used (Cure/Complete vs Failure/Relapse); Reference = Resistant to Drug Used |
OR of Treatment Success if Susceptible to the Drug Used (Cure/Complete vs Failure/Relapse); Reference = Resistant to Drug Used |
||
| No. Given the Drug, Unadjusted OR (95% CI) | No. Given the Drug, Adjusted ORb (95% CI) | No. Given the Drug, Unadjusted OR (95% CI) | No. Given the Drug, Adjusted ORb (95% CI) | |
| Pyrazinamide: | 1275 | 1275 | 68 | 68 |
| 21 studies at recommended and 2 studies at higher | 2.0 (1.4–3.0) | 2.0 (1.3–3.0) | 3.9 (1.0–16.2) | No convergencec |
| Ethambutol: | 1148 | 1148 | 185 | 185 |
| 17 studies at recommended and 3 studies at higher | 1.6 (1.1–2.3) | 1.5 (1.1–2.4) | 2.0 (.9–4.7) | 2.2 (1.0–5.3) |
| Streptomycin: | 197 | 197 | 434 | 434 |
| 7 studies at recommended and 12 at studies higher | 1.1 (.2–5.0) | No convergencec | 1.8 (.9–3.4) | 1.8 (.9–3.5) |
| Capreomycin: | 240 | 240 | 235 | 235 |
| 7 studies at recommended and 2 studies at higher | 3.5 (.8–15) | 4.7 (.9–25.0) | No convergencec | No convergencec |
| Cycloserine: | 2489 | 2489 | 215 | 215 |
| 11 studies at recommended and 5 studies at higher | 2.5 (1.2–4.6) | 2.3 (1.4–4.1) | 2.0 (.7–5.3) | No convergencec |
| PAS: | 782 | 782 | 163 | 163 |
| 5 studies at recommended and 6 studies at higher | 2.5 (1.6–4.0) | 2.2 (1.1–4.7) | 1.5 (.5–4.9) | No convergencec |
Bold values indicate statistically significant results.
Abbreviations: CI, confidence interval; DST, drug susceptibility testing; OR, odds ratio; PAS, para-aminosalicylic acid.
a All studies that either did not provide or used less than recommended critical concentrations were excluded from this analysis.
b Models adjusted for age, sex, extent of disease, past history of treatment with first- and second-line drugs, and human immunodeficiency virus (HIV) coinfection. The number of missing values for each covariate which were imputed were as follows: age, 25; sex, 3; extent of disease, 175 (1.9%); past treatment with first-line drugs, 508 (5.7%); past treatment with second-line drugs, 852 (9.5%); HIV coinfection, 1292 (14.3%).
c Multivariable models did not converge (too few observations and too much heterogeneity).